Table 1.
Studies investigating pulmonary metastasectomy in ACC.
| Study | n (ACC PMs) | Intervention | Outcomes | Ref. |
|---|---|---|---|---|
| Girelli et al. (2017) |
109 | PM: 83.5% CR 16.5% IR |
5-year OS: 66.8% 10-year OS: 40.5% |
[134] |
| Park et al. (2022) |
18 | PM: 100% CR |
1-year DFS: 88.9% 3-year DFS: 38.9% 5-year DFS: 32.4% 8-year DFS: 0% |
[135] |
| Locati et al. (2005) |
20 | PM: 55% CR 45% IR |
Median OS: 78 mo. (CR) vs. 52 mo. (IR) Median PFS: 30 mo. (CR) vs. 15 mo. (IR) |
[136] |
| Liu et al. (1999) |
16 | PM: 81% CR 19% IR |
5-year OS: 84% | [137] |
| Mazer et al. (1988) |
13 | PM | 5-year OS: 63% | [138] |
| AlShammari et al. (2020) |
11 | PM | 5-year OS: 100% | [139] |
| Bobbio et al. (2008) |
9 | PM | Median OS: 72 mo. | [140] |
| Winter et al. (2008) |
6 | PM | 5-year OS: 33.3% Median OS: 43.5 mo. |
[141] |
| Ishida et al. (2020) |
5 | PM | 5-year OS: 100% | [50] |
| Lu et al. (2019) |
3 | PM | 2-year OS: 100% 5-year OS: 100% |
[142] |
Abbreviations: ACC, adenoid cystic carcinoma; CR, complete resection; DFI, disease-free interval; DFS, disease-free survival; HNC, head and neck cancer; IR, incomplete resection; mo., months; OS, overall survival; PFS, progression-free survival; PM, pulmonary metastasectomy.